Clinical trials
Active, not recruiting Carcinoma, Renal Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
155 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2014 | 4 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 11 |
| 2018 | 8 |
| 2019 | 17 |
| 2020 | 17 |
| 2021 | 15 |
| 2022 | 22 |
| 2023 | 21 |
| 2024 | 9 |
| 2025 | 8 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 155 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 15 |
| M.D. Anderson Cancer Center | 14 |
| Merck Sharp & Dohme LLC | 9 |
| AstraZeneca | 4 |
| Bristol-Myers Squibb | 3 |
| City of Hope Medical Center | 3 |
| Duke University | 3 |
| Exelixis | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Renal Cell | 155 |
| Melanoma | 38 |
| Carcinoma, Non-Small-Cell Lung | 37 |
| Kidney Neoplasms | 29 |
| Squamous Cell Carcinoma of Head and Neck | 22 |
| Colorectal Neoplasms | 20 |
| Carcinoma, Transitional Cell | 17 |
| Ovarian Neoplasms | 17 |
| Neoplasm Metastasis | 14 |
| Stomach Neoplasms | 14 |
Trials
Showing 1 to 25 of 155. Each trial links to its page on Pharma Observatory.
55 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.